

Emergent BioSolutions Inc.
Form 4
April 05, 2016

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Kramer Robert

(Last) (First) (Middle)
400 PROFESSIONAL DR, SUITE 400
(Street)

GAITHERSBURG, MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [EBS]

3. Date of Earliest Transaction
(Month/Day/Year)
04/01/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
EVP, Corporate Services Divisi

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price (A) or (D)		
Common Stock ⁽¹⁾	04/01/2016		M		11,531 A \$ 14.41	91,607	D
Common Stock ⁽¹⁾	04/01/2016		S		11,531 D \$ 35.49 ⁽⁵⁾	80,076	D
Common Stock ⁽²⁾	04/01/2016		M		3,939 A \$ 14.67	84,015	D
Common Stock ⁽²⁾	04/01/2016		S		3,939 D \$ 35.74 ⁽⁶⁾	80,076	D
	04/01/2016		M		17,354 A	97,430	D

Edgar Filing: Emergent BioSolutions Inc. - Form 4

Common Stock ⁽³⁾					\$ 28.09		
Common Stock ⁽³⁾	04/01/2016	S	17,354	D	\$ 35.48 ⁽⁷⁾	80,076	D
Common Stock ⁽⁴⁾	04/01/2016	M	5,503	A	\$ 29	85,579	D
Common Stock ⁽⁴⁾	04/01/2016	S	5,503	D	\$ 35.66 ⁽⁸⁾	80,076	D
Common Stock ⁽⁹⁾	04/01/2016	S	445	D	\$ 35.93 ⁽¹⁰⁾	79,631	D
Common Stock ⁽⁹⁾	04/01/2016	S	1,855	D	\$ 35.8 ⁽¹¹⁾	77,776	D
Common Stock ⁽⁹⁾	04/01/2016	S	2,945	D	\$ 35.73 ⁽¹²⁾	74,831	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option ⁽¹⁾	\$ 14.41	04/01/2016		M	11,531	⁽¹³⁾ 11/04/2019	Common Stock	11,531
Stock Option ⁽²⁾	\$ 14.67	04/01/2016		M	3,939	⁽¹⁴⁾ 03/11/2020	Common Stock	3,939
	\$ 28.09	04/01/2016		M	17,354	⁽¹⁵⁾ 03/10/2021		17,354

Stock Option (3)								Common Stock
Stock Option (4)	\$ 29	04/01/2016	M	5,503	(16)	03/09/2022	Common Stock	5,503

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Kramer Robert 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG, MD 20879			EVP, Corporate Services Divisi	

Signatures

/s/ Eric Burt,
attorney-in-fact

04/05/2016

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Consists of an option granted under the company's stock incentive plan on November 5, 2012.
- (2) Consists of an option granted under the company's stock incentive plan on March 12, 2013.
- (3) Consists of an option granted under the company's stock incentive plan on March 11, 2014.
- (4) Consists of an option granted under the company's stock incentive plan on March 10, 2015.
- (5) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.11 to \$36.34, inclusive.
- (6) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.37 to \$36.32, inclusive.
- (7) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.07 to \$36.35, inclusive.
- (8) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.12 to \$36.42, inclusive.
- (9) Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
- (10) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.91 to \$36.00, inclusive.
- (11) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.50 to \$36.13, inclusive.
- (12) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.50 to \$36.32, inclusive.
- (13) The option vested in three equal installments in November 2013, 2014 and 2015.
- (14) The option vest in three equal installments in March 2014, 2015 and 2016.

Edgar Filing: Emergent BioSolutions Inc. - Form 4

(15) The option vest in three equal installments in March 2015, 2016 and 2017.

(16) The option vest in three equal installments in March 2016, 2017 and 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.